{
  "trial_id": "NCT00590681",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Disease-Specific Concerns Histologically confirmed GBM as determined by central pathology review",
      "label": "met"
    },
    {
      "criterion": "Supratentorial location",
      "label": "met"
    },
    {
      "criterion": "18 years of age; Karnofsky performance status > 60;",
      "label": "unknown"
    },
    {
      "criterion": "Tumor-related contrast enhancement on initial and post-operative Gd-MRI;",
      "label": "unknown"
    },
    {
      "criterion": "Recovery from effects of surgery and/or its complications prior to initiating radiotherapy;",
      "label": "unknown"
    },
    {
      "criterion": "Radiotherapy must begin < 5 weeks following surgery;",
      "label": "unknown"
    },
    {
      "criterion": "Pre-and post-operative Gd-MRI prior to the initiation of radiotherapy;",
      "label": "unknown"
    },
    {
      "criterion": "Adequate hematological, renal, and hepatic function:hemoglobin > 10 grams hematocrit > 30%, platelets > 100,000 per mm3, BUN < 25 mg/dl, Creatinine < 1.5 mg/dl, Total bilirubin < 1.5 mg/dl, SGOT or SGPT < twice institutional normal range;",
      "label": "unknown"
    },
    {
      "criterion": "Subjects must not be pregnant or nursing",
      "label": "met"
    },
    {
      "criterion": "Use of effective means of contraception (men and women) in subjects of child-bearing (women) and at all ages (men)",
      "label": "unknown"
    },
    {
      "criterion": "Study-specific signed informed consent",
      "label": "met"
    },
    {
      "criterion": "Ability to comply with study follow-up procedures.",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "a. Disease-Specific Concerns: malignant gliomas graded less than GBM;",
      "label": "triggers"
    },
    {
      "criterion": "b. Bevacizumab-Specific Concerns: Inadequately controlled hypertension (defined as systolic blood pressure 150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications);",
      "label": "triggers"
    },
    {
      "criterion": "History of myocardial infarction or unstable angina within 6 months prior to study enrollment;",
      "label": "unknown"
    },
    {
      "criterion": "History of stroke or transient ischemic attack within 6 months prior to study enrollment;",
      "label": "unknown"
    },
    {
      "criterion": "New York Heart Association (NYHA) Grade II or greater CHF (see Appendix E);",
      "label": "unknown"
    },
    {
      "criterion": "Significant vascular disease (e.g., aortic aneurysm, aortic dissection);",
      "label": "unknown"
    },
    {
      "criterion": "Symptomatic peripheral vascular disease;",
      "label": "unknown"
    },
    {
      "criterion": "Evidence of bleeding diathesis or coagulopathy;",
      "label": "unknown"
    }
  ],
  "notes": "Patient has a history of anaplastic astrocytoma and is currently experiencing progressive lower extremity weakness and urinary retention. The patient's overall health status may make them ineligible for the study.",
  "_meta": {
    "topic_id": "1",
    "trial_id": "NCT00590681",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}